Ferrari Lynne R
Perioperative Services, Children's Hospital, Boston, Massachusetts 02115, USA.
Curr Opin Anaesthesiol. 2008 Jun;21(3):401-5. doi: 10.1097/ACO.0b013e3282faa2f0.
With the rising incidence of diabetes mellitus in the United States today, more and more patients with this comorbidity will present for surgical or interventional procedures. Treatments are becoming more varied and complex so anesthesiologists must be familiar with new drugs and delivery modalities used in the treatment of this patient population.
New types of insulin have revolutionized diabetic care. The introduction of rapid acting and long acting insulin has enabled more precise glucose control to be achieved. New delivery modes of insulin both by the inhaled/buccal route and premeasured pen have been introduced. The newer oral hypoglycemic agents are also in use and have mechanisms of action that differ from the older treatments.
Anesthesiologists must keep themselves updated with the rapidly changing treatment options for diabetic patients with both type 1 and type 2 diseases. The mechanism of action and duration of newer drugs are important for clinicians to know when managing intraoperative serum glucose control.
在当今美国,糖尿病发病率不断上升,越来越多患有这种合并症的患者将接受外科手术或介入治疗。治疗方法日益多样和复杂,因此麻醉医生必须熟悉用于治疗这类患者群体的新药和给药方式。
新型胰岛素彻底改变了糖尿病护理。速效和长效胰岛素的引入使更精确的血糖控制得以实现。已推出通过吸入/口腔途径和预充式笔的胰岛素新给药方式。新型口服降糖药也在使用,其作用机制与旧疗法不同。
麻醉医生必须紧跟1型和2型糖尿病患者快速变化的治疗选择。在管理术中血糖控制时,临床医生了解新药的作用机制和持续时间很重要。